237 related articles for article (PubMed ID: 15285704)
1. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.
Srivastava IK; Ulmer JB; Barnett SW
Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S33-52. PubMed ID: 15285704
[TBL] [Abstract][Full Text] [Related]
2. Role of neutralizing antibodies in protective immunity against HIV.
Srivastava IK; Ulmer JB; Barnett SW
Hum Vaccin; 2005; 1(2):45-60. PubMed ID: 17038830
[TBL] [Abstract][Full Text] [Related]
3. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
4. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
[TBL] [Abstract][Full Text] [Related]
5. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
Sadanand S; Suscovich TJ; Alter G
Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
[TBL] [Abstract][Full Text] [Related]
6. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
van Gils MJ; Sanders RW
Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
[TBL] [Abstract][Full Text] [Related]
7. Correlations between HIV-1 clades and HIV-1 antibody neutralization sensitivity: significant for vaccine development?
van Gils MJ; Schuitemaker H
Curr HIV Res; 2010 Dec; 8(8):579-86. PubMed ID: 21054254
[TBL] [Abstract][Full Text] [Related]
8. Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk.
Martinez DR; Vandergrift N; Douglas AO; McGuire E; Bainbridge J; Nicely NI; Montefiori DC; Tomaras GD; Fouda GG; Permar SR
J Virol; 2017 May; 91(9):. PubMed ID: 28202762
[TBL] [Abstract][Full Text] [Related]
9. Toward an antibody-based HIV-1 vaccine.
Hoxie JA
Annu Rev Med; 2010; 61():135-52. PubMed ID: 19824826
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
11. Role of humoral immunity in host defense against HIV.
Baum LL
Curr HIV/AIDS Rep; 2010 Feb; 7(1):11-8. PubMed ID: 20425053
[TBL] [Abstract][Full Text] [Related]
12. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.
Koff WC
Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891
[TBL] [Abstract][Full Text] [Related]
13. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
14. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.
Karlsson Hedestam GB; Fouchier RA; Phogat S; Burton DR; Sodroski J; Wyatt RT
Nat Rev Microbiol; 2008 Feb; 6(2):143-55. PubMed ID: 18197170
[TBL] [Abstract][Full Text] [Related]
15. Prospects for a globally effective HIV-1 vaccine.
Excler JL; Robb ML; Kim JH
Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
[TBL] [Abstract][Full Text] [Related]
16. HIV Vaccination: A Roadmap among Advancements and Concerns.
Trovato M; D'Apice L; Prisco A; De Berardinis P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29671786
[TBL] [Abstract][Full Text] [Related]
17. HIV vaccine: hopes and hurdles.
Chhatbar C; Mishra R; Kumar A; Singh SK
Drug Discov Today; 2011 Nov; 16(21-22):948-56. PubMed ID: 21889604
[TBL] [Abstract][Full Text] [Related]
18. Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses.
Heeney JL
Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S53-64. PubMed ID: 15285705
[TBL] [Abstract][Full Text] [Related]
19. HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity.
Wren L; Kent SJ
Hum Vaccin; 2011 Apr; 7(4):466-73. PubMed ID: 21389779
[TBL] [Abstract][Full Text] [Related]
20. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
